{"product_id":"cwbr-vrio-analysis","title":"CohBar, Inc. (CWBR): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the sustainable competitive edge for CohBar, Inc. (CWBR) hinges on a rigorous VRIO analysis, which we've distilled into key insights regarding its Value, Rarity, Inimitability, and Organization. Discover immediately which core capabilities truly set this business apart and which areas require strategic focus to maintain market leadership. Dive into the full breakdown below to see the complete picture.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCohBar, Inc. (CWBR) - VRIO Analysis: Mito+ Therapeutic Technology Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eBefore we dive in, you need to know the landscape has shifted dramatically for the assets once housed under \u003cstrong\u003eCohBar, Inc.\u003c\/strong\u003e (CWBR). The company was suspended and expected to be delisted from Nasdaq in November 2023, and the planned merger with Morphogenesis, Inc. was reportedly cancelled around the same time due to listing application issues. The technology platform you are asking about, Mito+, now exists in a complex legacy or has been superseded, as the successor entity, \u003cstrong\u003eTuHURA Biosciences, Inc.\u003c\/strong\u003e (HURA), is now focused on immuno-oncology assets like IFx-2.0 and TBS-2025, not mitochondria-based therapeutics. Still, we can assess the platform’s inherent strategic position based on its description, using the current financial context of the successor entity to ground the \u003cstrong\u003eOrganization\u003c\/strong\u003e and \u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e scoring.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the current financial environment for the entity that emerged from that corporate activity: \u003cstrong\u003eTuHURA Biosciences, Inc.\u003c\/strong\u003e reported \u003cstrong\u003e$0.00\u003c\/strong\u003e in revenue for the third quarter ending September 30, 2025. Net cash outflows from operating activities for the first nine months of 2025 were \u003cstrong\u003e($22.1) million\u003c\/strong\u003e. This burn rate highlights the intense capital requirement for clinical-stage development, which is the environment any asset, including the legacy Mito+ platform, would face.\u003c\/p\u003e\n\n\u003ch\u003eVRIO Framework Assessment: Mito+ Platform\u003c\/h\u003e\n\n\u003cp\u003eThe VRIO framework helps us see if the core technology offers a durable edge. For the Mito+ platform, the assessment hinges on whether the foundational science remains proprietary and if the current corporate structure is geared to exploit it, which, based on the latest data, seems unlikely for the original indication.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The platform’s value proposition is creating first-in-class mitochondria-based therapeutics (MBTs) for chronic and age-related diseases, offering a novel mechanism of action. This is definitely high-value if proven clinically effective, as it addresses large, unmet medical needs like diabetes or neurodegeneration. The potential market size for a successful MBT in a major chronic disease dwarfs a single oncology indication.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The specific focus on naturally occurring mitochondrial-derived peptides as a drug class is quite rare in the current therapeutic landscape. Most biotech focus remains on monoclonal antibodies or gene therapy. This scarcity of direct, platform-level competitors in the MBT space suggests a rare capability, provided the underlying IP is sound.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Imitability is high because it relies on foundational, proprietary scientific discovery and a deep, specialized knowledge base. Replicating this isn't just about copying a molecule; it requires recreating years of specialized cell biology and peptide engineering expertise. This is a high barrier to entry, making it difficult to copy quickly.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The original organization was structured around exploiting this platform to generate multiple drug candidates. However, the current organization, \u003cstrong\u003eTuHURA Biosciences, Inc.\u003c\/strong\u003e, is clearly structured around Morphogenesis’s oncology pipeline (IFx-2.0 and TBS-2025). With \u003cstrong\u003e51.2 million\u003c\/strong\u003e shares outstanding as of September 30, 2025, and R\u0026amp;D expenses of \u003cstrong\u003e$4.9 million\u003c\/strong\u003e for Q3 2025, the resources are allocated elsewhere. If the Mito+ platform is not actively managed or funded, the organization component scores low for this specific asset, regardless of its inherent V\/R\/I.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e The potential advantage is \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e, provided the company successfully translates platform discoveries into approved drugs and maintains the organizational focus to support them. Given the current corporate structure’s shift, the actual advantage for the Mito+ platform is likely \u003cstrong\u003eCompetitive Parity\u003c\/strong\u003e or even a \u003cstrong\u003eCompetitive Disadvantage\u003c\/strong\u003e due to lack of organizational support, despite the strong V\/R\/I of the science itself.\u003c\/p\u003e\n\n\u003cp\u003eHere is a summary of the assessment based on the platform's inherent qualities versus the current corporate reality:\u003c\/p\u003e\n\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment for Mito+ Platform (Inherent)\u003c\/td\u003e\n    \u003ctd\u003eScore (1=Low, 4=High)\u003c\/td\u003e\n    \u003ctd\u003eFinancial Context (TuHURA Biosciences, Inc. Q3 2025 Data)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eCreates first-in-class MBTs for chronic\/age-related diseases.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eR\u0026amp;D Spend: \u003cstrong\u003e$4.9 million\u003c\/strong\u003e (3 months ended 9\/30\/2025)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eSpecific focus on mitochondrial-derived peptides is rare.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eCash Burn: Net cash outflow of \u003cstrong\u003e($22.1) million\u003c\/strong\u003e (9 months ended 9\/30\/2025)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eHigh; relies on foundational, proprietary scientific discovery.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eShares Outstanding: Approx. \u003cstrong\u003e51.2 million\u003c\/strong\u003e (as of 9\/30\/2025)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eOriginal structure was aligned; current structure is oncology-focused.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eATM Facility: Up to \u003cstrong\u003e$50 Million\u003c\/strong\u003e available\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eSustained, if the asset were the primary focus.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eTemporary\/None\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eRevenue: \u003cstrong\u003e$0.00\u003c\/strong\u003e (Q3 2025)\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe key takeaway for you is that the scientific potential (V, R, I) of the Mito+ platform is strong, but the corporate structure (O) is not currently organized to capture that value, which is a defintely fatal flaw for any asset.\u003c\/p\u003e\n\n\u003cp\u003eIf you are looking to value the legacy IP, you must model the cost of re-establishing an organization around it, which means factoring in the capital needed to fund operations until revenue, perhaps modeling a cash runway based on the \u003cstrong\u003e$22.1 million\u003c\/strong\u003e outflow over nine months.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCohBar, Inc. (CWBR) - VRIO Analysis: Broad Intellectual Property Estate\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProvides legal protection for key drug candidates like CB4211 and the underlying technology, securing future revenue streams. The U.S. patent granted for CB4211 extends protection to at least \u003cstrong\u003e2037\u003c\/strong\u003e, not including any potential patent term extension.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHaving over $\\mathbf{13}$ issued patents and $\\mathbf{65}$ filed applications (as of 2021 data) in this niche is a significant moat.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Metric\u003c\/td\u003e\n\u003ctd\u003eAmount (As of 2021)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIssued Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFiled Patent Applications\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt; 65\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCB4211 Patent Term (US, minimum)\u003c\/td\u003e\n\u003ctd\u003eAt least \u003cstrong\u003e2037\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate to high; while patents expire, the breadth of coverage makes broad imitation difficult and costly.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe portfolio is directed to novel analogs of mitochondrially encoded peptides and methods of treating a variety of diseases.\u003c\/li\u003e\n\u003cli\u003eThe company has discovered more than \u003cstrong\u003e100\u003c\/strong\u003e mitochondrial derived peptides and generated over \u003cstrong\u003e1,000\u003c\/strong\u003e analogs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company actively pursues IP protection in strategically important markets, showing a clear strategy.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLegal fees associated with protecting the company's intellectual property portfolio were noted in Q1 2022 General and Administrative Expenses.\u003c\/li\u003e\n\u003cli\u003eThe strategy generally seeks patent protection in the United States and international jurisdictions with significant potential market opportunity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary, as patents have finite lives, but strong in the near-to-medium term.\u003c\/p\u003e\n\u003cp\u003eCash, Cash Equivalents and Investments as of June 30, 2022, were \u003cstrong\u003e\\$20.1 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCohBar, Inc. (CWBR) - VRIO Analysis: CB4211 Lead Clinical Asset\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eCB4211 Lead Clinical Asset\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eRepresents the most advanced asset, having demonstrated positive effects in a Phase 1a\/1b trial for NASH and obesity, potentially reaching late-stage trials by late 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePrimary endpoint met: well-tolerated and appeared safe with no serious adverse events in the Phase 1a\/1b study.\u003c\/li\u003e\n\u003cli\u003eDose tested in Phase 1b: 25 mg CB4211 administered subcutaneously 1x daily for 4 weeks.\u003c\/li\u003e\n\u003cli\u003eNASH affects approximately 30 million adults in the U.S.\u003c\/li\u003e\n\u003cli\u003eCB4211 is the first-ever mitochondria-based therapy to reach clinical testing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomarker Endpoint (Phase 1b, 4 Weeks)\u003c\/td\u003e\n\u003ctd\u003eCB4211 (25 mg, n=11)\u003c\/td\u003e\n\u003ctd\u003ePlacebo (n=9)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eALT (% reduction from baseline)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-21%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAST (% reduction from baseline)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-28%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-11%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlucose (% reduction from baseline)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProportion with \u0026gt;17 U\/L decrease in ALT\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eLiver fat content reduction (MRI-PDFF) was -5.03% for CB4211 versus -4.88% for placebo.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate; many companies have lead assets, but CB4211’s mechanism as an MBT is relatively unique.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePlatform has discovered over 100 mitochondrial derived peptides and generated over 1,000 analogs.\u003c\/li\u003e\n\u003cli\u003eMechanism: MOTS-c modulators, Epigenetic drug.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eLow, due to the time and capital required to replicate clinical trial success and secure related IP.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D Expenses for Q1 2021 were $2.7 million.\u003c\/li\u003e\n\u003cli\u003eQuarterly cash burn was approximately $1.9 million (Q3 2022).\u003c\/li\u003e\n\u003cli\u003eThe company executed a 1-for-30 reverse stock split on September 23, 2022, to maintain Nasdaq listing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eManagement focus is clearly directed toward advancing this compound through clinical milestones.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eManagement reiterated an Investigational New Drug (IND) application timeline for a different lead program (CB5138-3) for H2 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained, if it achieves regulatory approval and market entry.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCohBar, Inc. (CWBR) - VRIO Analysis: Pipeline Diversity in Age-Related Diseases\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue: Mitigates single-asset risk by having four preclinical programs targeting high-need areas like IPF, cancer immunotherapy, and T2D.\u003c\/h\u003e\n\u003cp\u003eThe pipeline includes four preclinical programs: CB5138 Analogs for fibrotic diseases, CB5064 Analogs for COVID-19 associated ARDS, MBT3 Analogs for cancer immunotherapy, and CB4211 for NASH and obesity, which was in Phase 1b as of Q1 2021.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: Moderate; many biotechs have preclinical pipelines, but the focus across multiple distinct age-related pathologies is notable.\u003c\/h\u003e\n\u003cp\u003eThe platform has generated more than 65 new provisional patent applications covering newly-identified MDPs and their novel, improved analogs.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: Moderate; competitors can pursue similar targets, but CohBar has a head start with its platform-derived analogs.\u003c\/h\u003e\n\u003cp\u003eThe company is advancing a pipeline of peptide analogs developed from its Mito+ platform.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: The structure supports parallel development tracks, though resources are likely stretched thin given the small team size.\u003c\/h\u003e\n\u003cp\u003eThe company employed 9 full-time employees as of a recent report. The cash burn for Q3 2022 was approximately $1.9 million. Cash and investments stood at $18.3 million as of Q3 2022.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Temporary, dependent on which program advances fastest.\u003c\/h\u003e\n\u003cp\u003eThe goal for the lead program, CB5138-3 for IPF, was to file an Investigational New Drug (IND) application in the second half of 2023. The net loss for Q3 2022 was $2.4 million.\u003c\/p\u003e\n\n\u003cp\u003eThe diversity across the pipeline is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgram Candidate\u003c\/td\u003e\n\u003ctd\u003eTarget Indication\u003c\/td\u003e\n\u003ctd\u003eDevelopment Stage (Contextual)\u003c\/td\u003e\n\u003ctd\u003eFinancial Metric Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCB4211\u003c\/td\u003e\n\u003ctd\u003eNASH and Obesity\u003c\/td\u003e\n\u003ctd\u003ePhase 1b\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Expenses Q1 2021: $2.7 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCB5138-3\u003c\/td\u003e\n\u003ctd\u003eIdiopathic Pulmonary Fibrosis (IPF)\u003c\/td\u003e\n\u003ctd\u003eIND-enabling activities\u003c\/td\u003e\n\u003ctd\u003eCash Reserves Q3 2022: $18.3 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCB5064 Analogs\u003c\/td\u003e\n\u003ctd\u003eCOVID-19 associated ARDS\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eCurrent Ratio (Latest): 15.69\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMBT3 Analogs\u003c\/td\u003e\n\u003ctd\u003eCancer Immunotherapy\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eEmployees: 9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eLiquidity metrics from the most recent reporting period include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash Ratio: 5.74\u003c\/li\u003e\n\u003cli\u003eCurrent Ratio: 15.69\u003c\/li\u003e\n\u003cli\u003eQuick Ratio: 15.69\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCohBar, Inc. (CWBR) - VRIO Analysis: Zero Debt Financial Structure\n\u003c\/h2\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe zero debt financial structure provides significant financial flexibility, which is crucial for a clinical-stage company with negative operating cash flow. The Operating Cash Flow (ttm) was reported as \u003cstrong\u003e-9,555,999 USD\u003c\/strong\u003e. The company maintained a Total Debt (mrq) of \u003cstrong\u003e0 USD\u003c\/strong\u003e as of the most recent reporting period. This structure reduces fixed obligations associated with debt servicing.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nA zero debt position is considered high rarity for a company at this clinical stage, as many peers utilize significant debt or convertible notes to fund operations. The Debt \/ Equity Ratio is reported as \u003cstrong\u003e0%\u003c\/strong\u003e.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe current capital structure, reflecting past financing decisions, is not an easily copied operational trait, resulting in low imitability.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe organization is structured to rely on equity financing or operational cash flow, evidenced by the high liquidity metrics supporting operations despite negative cash flow from operations.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nA sustained competitive advantage is maintained as long as the company preserves its net cash position, supported by strong liquidity ratios.\n\u003c\/p\u003e\n\n\u003cp\u003e\nFinancial Metrics Supporting Zero Debt Structure (Millions USD, unless otherwise noted):\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Most Recent\/TTM)\u003c\/th\u003e\n\u003cth\u003ePeriod End Date\u003c\/th\u003e\n\u003cth\u003eSource\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003emrq\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Cash (mrq)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.08\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMar 31, 2023\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.19\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJun '23\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Current Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJun '23\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt \/ Equity Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15.935\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003emrq\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Ratio (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.74\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTTM\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow (ttm)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-9.56\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ettm\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\nLiquidity Position Indicators:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nThe Cash Ratio, the most conservative liquidity measure, is \u003cstrong\u003e5.74\u003c\/strong\u003e, indicating substantial cash over current liabilities.\n\u003c\/li\u003e\n\u003cli\u003e\nThe Current Ratio stands at \u003cstrong\u003e15.935\u003c\/strong\u003e, demonstrating the ability to meet short-term obligations using all current assets.\n\u003c\/li\u003e\n\u003cli\u003e\nAs of Q3 2022, cash reserves were \u003cstrong\u003e$18.3 million\u003c\/strong\u003e with a quarterly cash burn of approximately \u003cstrong\u003e$1.9 million\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nThe Debt-Equity Ratio has been reported as lowest at \u003cstrong\u003e-129.54%\u003c\/strong\u003e in the last five Semi-Annual periods, indicating a reduction in borrowing relative to equity capital.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCohBar, Inc. (CWBR) - VRIO Analysis: High Institutional Ownership Concentration\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A \u003cstrong\u003e100.00%\u003c\/strong\u003e institutional holding (as per latest data) suggests strong conviction from sophisticated investors who understand the science.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e \u003cstrong\u003eVery high\u003c\/strong\u003e; this level of concentration among institutions is unusual and signals tight control\/belief.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e \u003cstrong\u003eLow\u003c\/strong\u003e; this is a historical artifact of past funding rounds and current shareholder base.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is highly accountable to a small group of sophisticated financial stakeholders.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e \u003cstrong\u003eTemporary\u003c\/strong\u003e; ownership can shift, but currently provides stability.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes key financial and ownership statistics relevant to this analysis, based on the latest available data for the CWBR ticker prior to or during its transition phase:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.19 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Price (Last Traded\/Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.41\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding (Approximate)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.91 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Institutional Owners (SEC Filers)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Held by Reporting Institutions\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e181,490\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Institutional Holding Percentage (Alternative Data)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.84%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFloat (Approximate)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.48 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther details on the ownership structure and financial context include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe latest reported SEC Form 8-K filing date was \u003cstrong\u003eOctober 25, 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's reported EBIT Growth (5y) was \u003cstrong\u003e-1.10%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Price to Book Value was reported as \u003cstrong\u003e0.13\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company has historically financed operations primarily with proceeds from sales of its equity securities, private placements, and warrant exercises, with no revenues from operations expected in the near future as of a \u003cstrong\u003eMarch 31, 2020\u003c\/strong\u003e filing.\u003c\/li\u003e\n\u003cli\u003eThe company's Debt to EBITDA (average) was reported as \u003cstrong\u003eNegative Net Debt\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCohBar, Inc. (CWBR) - VRIO Analysis: World-Renowned Expertise in Mitochondrial Biology\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: The scientific team possesses deep, foundational knowledge that underpins the entire drug discovery process, which is hard to replicate.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: High; this specific, deep expertise is concentrated among the founders and key scientific personnel.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Sustained; key personnel are difficult to poach, and institutional knowledge is embedded.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: This expertise is the engine driving the Mito+ platform's innovation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained, as long as the key scientific leaders remain with CohBar.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMitochondrial Derived Peptides (MDPs) Discovered\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 100\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalogs Generated\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOver 1,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead Compound in Phase 1a\/1b Trial (CB4211)\u003c\/td\u003e\n\u003ctd\u003e1 (as of 2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical Programs\u003c\/td\u003e\n\u003ctd\u003e4 (as of 2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial data associated with the operation of the mitochondrial therapeutics focus (Q3 2022):\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Loss: \u003cstrong\u003e$2.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash Reserves: \u003cstrong\u003e$18.3 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial outcome related to the expertise's legacy:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOriginal CohBar shareholders retained stake in combined entity (post-2023 merger): \u003cstrong\u003e15%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCohBar, Inc. (CWBR) - VRIO Analysis: Specialization in Chronic and Age-Related Diseases\n\u003c\/h2\u003e\n\u003cp\u003eThe therapeutic area of focus for CohBar, Inc. is situated within the broader mitochondrial-based therapeutics market, which is projected to expand significantly:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMarket Metric\u003c\/th\u003e\n\u003cth\u003eValue\/Year\u003c\/th\u003e\n\u003cth\u003eCAGR\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMitochondrial-Based Therapeutics Market Value\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eUSD 1.7 billion\u003c\/strong\u003e (2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10.8%\u003c\/strong\u003e (to 2030)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMitochondrial Disease Therapies Market Value\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eUSD 420 million\u003c\/strong\u003e (2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e28.5%\u003c\/strong\u003e (to 2030)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMitochondrial-Based Therapeutics Market Value\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eUSD 460.5 million\u003c\/strong\u003e (2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7.8%\u003c\/strong\u003e (to 2035)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eSpecialization in Chronic and Age-Related Diseases\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Focuses R\u0026amp;D efforts on large, underserved markets where mitochondrial dysfunction is a known driver, increasing potential market size.\u003c\/p\u003e\n\u003cp\u003eCohBar develops mitochondria and peptides based therapeutics for chronic and age-related diseases, including:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCB4211: Therapeutic for nonalcoholic steatohepatitis (NASH) and obesity, demonstrated positive effects on reducing liver injury biomarkers in a Phase 1a\/1b clinical study in obese subjects with nonalcoholic fatty liver disease.\u003c\/li\u003e\n\u003cli\u003eCB5138 Analogs: In preclinical study for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.\u003c\/li\u003e\n\u003cli\u003eProduct portfolio also includes drugs such as CB4209, SHLP-6, and SHLP-2, addressing Type-2 diabetes, cancer, and cardiovascular diseases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many biotechs target aging, but CohBar’s specific focus on the mechanism is more specialized.\u003c\/p\u003e\n\u003cp\u003eThe company's technology platform involves identifying nucleic acid sequences encoding native peptides in the mitochondrial genome to develop novel analogs (Mitochondrial Derived Peptides - MDPs).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEmployee Count: \u003cstrong\u003e14\u003c\/strong\u003e total employees.\u003c\/li\u003e\n\u003cli\u003ePrevalence context: Mitochondrial disease affects approximately \u003cstrong\u003e1 in 4,300 people\u003c\/strong\u003e in the United States.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can pivot, but CohBar has a multi-year head start in this specific area.\u003c\/p\u003e\n\u003cp\u003eFinancial data reflecting operational scale:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric (Period)\u003c\/th\u003e\n\u003cth\u003eAmount (USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Q3 2022)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Q3 2021)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Reserves (Q3 2022)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$18.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuarterly Cash Burn (Q3 2022)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$1.9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (as of Aug 31, 2023)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.85M\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEPS (12 months as of Aug 31, 2023)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$4.36\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The entire corporate strategy, from IP to pipeline, is aligned with this therapeutic focus.\u003c\/p\u003e\n\u003cp\u003eCorporate actions related to structure and compliance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReverse Stock Split: \u003cstrong\u003e1-for-30\u003c\/strong\u003e effective September 23, 2022.\u003c\/li\u003e\n\u003cli\u003eStock Listing: Trades on the OTC Markets exchange.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as therapeutic trends shift, but currently strong.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCohBar, Inc. (CWBR) - VRIO Analysis: Clinical Stage Operations\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The company has moved beyond pure discovery into human trials (Phase 1b), validating the transition from bench to bedside.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many companies are in preclinical, but fewer reach this stage with novel platforms.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; clinical progression is irreversible and requires years of regulatory navigation and capital deployment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Operations are geared toward meeting clinical trial demands, requiring specific regulatory and operational discipline.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as clinical progress is a sunk cost that competitors must match from scratch.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday. The last reported cash and investments balance was \u003cstrong\u003e$20.1 million\u003c\/strong\u003e as of June 30, 2022.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eReporting Period\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Quarterly Cash Burn\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$1.9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ3 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.74\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMost recent reporting period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15.69\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMost recent reporting period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,191,840\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecent quote\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003ePipeline progression milestones relevant to clinical operations:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCB4211 completed multi-center, randomized, double-blind, placebo-controlled \u003cstrong\u003ePhase 1a\/1b clinical study\u003c\/strong\u003e for NASH and obesity.\u003c\/li\u003e\n\u003cli\u003eTopline results for CB4211 Phase 1b showed it was well-tolerated with no serious adverse events.\u003c\/li\u003e\n\u003cli\u003eIND application for lead program CB5138-3 (targeting IPF) was on track for filing in \u003cstrong\u003eH2 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company had \u003cstrong\u003e10\u003c\/strong\u003e employees as of a recent profile date.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516147785877,"sku":"cwbr-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/cwbr-vrio-analysis.png?v=1740161588","url":"https:\/\/dcf-model.com\/es\/products\/cwbr-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}